Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In most patients with type 1 diabetes, adequate glycemic control is not achieved with insulin therapy alone. We evaluated the safety and efficacy of sotagliflozin, an oral inhibitor of sodium-glucose cotransporters 1 and 2, in combination with insulin treatment in patients with type 1 diabetes. METHODS: In this phase 3, double-blind trial, which was conducted at 133 centers worldwide, we randomly assigned 1402 patients with type 1 diabetes who were receiving treatment with any insulin therapy (pump or injections) to receive sotagliflozin (400 mg per day) or placebo for 24 weeks. The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, with no episodes of severe hypoglycemia or diabetic ketoacidosis after randomization. Secondary end points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressure, and mean daily bolus dose of insulin. RESULTS: A significantly larger proportion of patients in the sotagliflozin group than in the placebo group achieved the primary end point (200 of 699 patients [28.6%] vs. 107 of 703 [15.2%], P<0.001). The least-squares mean change from baseline was significantly greater in the sotagliflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points), weight (-2.98 kg), systolic blood pressure (-3.5 mm Hg), and mean daily bolus dose of insulin (-2.8 units per day) (P≤0.002 for all comparisons). The rate of severe hypoglycemia was similar in the sotagliflozin group and the placebo group (3.0% [21 patients] and 2.4% [17], respectively). The rate of documented hypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per liter) or below was significantly lower in the sotagliflozin group than in the placebo group. The rate of diabetic ketoacidosis was higher in the sotagliflozin group than in the placebo group (3.0% [21 patients] and 0.6% [4], respectively). CONCLUSIONS: Among patients with type 1 diabetes who were receiving insulin, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe hypoglycemia or diabetic ketoacidosis was larger in the group that received sotagliflozin than in the placebo group. However, the rate of diabetic ketoacidosis was higher in the sotagliflozin group. (Funded by Lexicon Pharmaceuticals; inTandem3 ClinicalTrials.gov number, NCT02531035 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Use of these processes may have contributed to the lower rates of ketoacidosis seen in some of the studies of these agents for adjunctive glycemic management in people with type 1 diabetes (314-316) compared with those that did not include preventative strategies (310,317).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [316]
In the citing paper
“Information on the safety and efficacy of combining MRAs with SGLT2 inhibitors in CKD is limited as only ∼4% of FIDELIO-DKD, ∼8% of FIGARO-DKD, ∼5% of DAPA-CKD, and no CREDENCE participants were prescribed such a combination.153,718,719,721”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
In the citing paper
“FIDELIO-DKD and FIGARO-DKD excluded patients with a potassium of >4.8 mmol/L, as MRAs cause hyperkalaemia.718,719”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
In the citing paper
“The placebo-controlled FIDELIO-DKD (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease) and FIGARO-DKD (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease) trials demonstrated for the non-steroidal MRA finerenone that these effects translate into reduced risk of kid”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [718]
Citations
Cites
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationSGLT2 Inhibitors May Predispose to Ketoacidosis
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1884 · Cited by 560
Weissberg-Benchell, J., Antisdel-Lomaglio, J., & Seshadri, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1079 · Cited by 551
Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050
Imperatore, G., Boyle, J. P., Thompson, T. J., Case, D., Dabelea, D., Hamman, R. F., Lawrence, J. M., Liese, A. D., Liu, L. L., Mayer-Davis, E. J., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0669 · Cited by 484
8. Pharmacologic Approaches to Glycemic Treatment
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s011 · Cited by 458
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433
Research works printed but not linked: 1
- Lyons SK, Diabetes Care
Cited by
Items 101–200 of 421
Peters, A. L., McGuire, D. K., Danne, T., Kushner, J. A., Rodbard, H. W., Dhatariya, K., Sawhney, S., Banks, P. L., Jiang, W., Davies, M. J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0924 · Cited by 44
Self-citationThe European Medicines Agency's approval of new medicines for type 2 diabetes
BLIND, E., Janssen, H., Dunder, K., & de Graeff, P. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13349 · Cited by 40
Billings, L. K., Parkin, C. G., & Price, D. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0163 · Cited by 39
Current and new pharmacotherapy options for non-alcoholic steatohepatitis
Sumida, Y., Yoneda, M., Ogawa, Y., Yoneda, M., Okanoue, T., & Nakajima, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1744564 · Cited by 38
“Sotagliflozin is effective in T1DM patients uncontrolled with insulin [94].”
BackgroundLeahy, J. (. L., Aleppo, G., Fonseca, V. A., Garg, S. K., Hirsch, I. B., McCall, A. L., McGill, J. B., & Polonsky, W. H. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00222 · Cited by 34
“Risk of DKAwas significant, as with other SGLT2 inhibitors [82, 83].”
BackgroundSelf-citationRecent Updates on Type 1 Diabetes Mellitus Management for Clinicians
Iqbal, A., Novodvorský, P., & Heller, S. R. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.42.1.3 · Cited by 45
“001) with similar rates of SH in both groups [37].”
BackgroundShah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
Self-citationTeo, Y. N., Ting, A. Z. H., Teo, Y. H., Chong, E. Y., Tan, J. T. A., Syn, N. L. X., Chia, A. Z. Q., Ong, H. T., Cheong, A. J. Y., Li, T. Y., et al. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00528-7 · Cited by 41
“SGLT1 inhibition delays intestinal glucose absorption, which may translate to increased concentrations of the endogenous glucagon-like peptide-1, resulting in enhanced cardiovascular benefits [34, 35].”
BackgroundSodium–glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class
da Silva, P. N., da Conceição, R. A., Maia, R. D. C., & Barbosa, M. L. D. C. (2018) · MedChemComm · doi:10.1039/c8md00183a · Cited by 37
Adjunctive therapy for glucose control in patients with type 1 diabetes
Harris, K., Boland, C. L., Meade, L. T., & Battise, D. M. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s141700 · Cited by 37
“4% of patients using sotagliflozin experienced genital mycotic infections.(67) However, some studies found no difference versus placebo.”
BackgroundResultInfluentialWang, H., Yang, J., Chen, X., Qiu, F., & Li, J. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.01.001 · Cited by 36
Posch, M. G., Walther, N., Ferrannini, E., Powell, D. R., Banks, P. L., Wason, S., & Dahmen, R. (2022) · Diabetes Care · doi:10.2337/dc21-2166 · Cited by 34
Self-citationThe role of SGLT-2 inhibitors in managing type 2 diabetes
Tsushima, Y., Lansang, M. C., & Makin, V. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20088 · Cited by 37
Li, K., & Xu, G. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12890 · Cited by 33
Hanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 35
“These findings indicate a potential therapeutic benefit in selected cases [44].”
Sridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 34
Du, F., Hinke, S. A., Cavanaugh, C., Polidori, D., Wallace, N., Kirchner, T., Jennis, M., Lang, W., Kuo, G., Gaul, M. D., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.248575 · Cited by 33
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174272 · Cited by 32
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 35
“They control glucose absorption in the small intestine as well as the reabsorption of roughly 10% of filtered glucose in the upper section of the renal proximal tubule [151,152].”
BackgroundIon channels and transporters in diabetic kidney disease
Spires, D. R., Manis, A. D., & Staruschenko, A. (2019) · Current topics in membranes · doi:10.1016/bs.ctm.2019.01.001 · Cited by 32
“Vallon et al. found that administering an SGLT2 inhibitor (empagliflozin) to the Akita mouse, a model of type 1 diabetes mellitus (T1DM), prevented hyperfiltration and reduced kidney hypertrophy and albumin excretion in the early stages of DKD.”
BackgroundInfluentialDanne, T., Pettus, J., Giaccari, A., Cariou, B., Rodbard, H. W., WEINZIMER, S. A., Bonnemaire, M., Sawhney, S., Stewart, J., Wang, S. Q., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0157 · Cited by 35
Self-citationRao, L., Ren, C., Luo, S., Huang, C., & Li, X. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01686-x · Cited by 29
Garg, S. V., Kaur, G., Renner, D. C., Lanning, M. S., Mason, E., Beatson, C. R., Ciesco, K., & Snell‐Bergeon, J. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0481 · Cited by 33
Self-citationThe Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Oe, Y., & Vallon, V. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020032 · Cited by 34
“This may involve upregulation of SGLT2 expression as indicated by rodent models of T1DM and T2DM (e.g., refs.”
BackgroundInfluentialBaker, C., Wason, S., Banks, P. L., Sawhney, S., Chang, A., Danne, T., Gesty‐Palmer, D., Kushner, J. A., McGuire, D. K., Mikell, F. L., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13825 · Cited by 30
Self-citationSrinuanchai, W., Nooin, R., Pitchakarn, P., Karinchai, J., Suttisansanee, U., Chansriniyom, C., Jarussophon, S., Temviriyanukul, P., & Nuchuchua, O. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113398 · Cited by 34
Azizogli, A., Vitti, M., Mishra, R., Osorno, L., Heffernan, C., & Kumar, V. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300143 · Cited by 36
Tricò, D., Mengozzi, A., Frascerra, S., Scozzaro, T., Mari, A., & Natali, A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02166 · Cited by 30
Ong, H. T., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Wee, C. F., Leong, S., Yip, A. S. Y., See, R. M., Ting, A. Z. H., Chia, A. Z. Q., et al. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106159 · Cited by 30
Tandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 32
“Inclusion criteria for BMI were not mentioned in any of the studies assessing sotagliflozin.(51,53,55) For the study assessing ipragliflozin, the inclusion criteria for BMI ranged from 20.”
BackgroundCaMKII and GLUT1 in heart failure and the role of gliflozins
Trum, M., Wagner, S., Maier, L. S., & Mustroph, J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165729 · Cited by 30
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
Chrysavgis, L., Papatheodoridi, A., Chatzigeorgiou, A., & Cholongitas, Ε. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15202 · Cited by 29
Sodium glucose cotransporters inhibitors in type 1 diabetes
Dellepiane, S., Nasr, M. B., Assi, E., Usuelli, V., Letizia, T., D’Addio, F., Zuccotti, G., & Fiorina, P. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.018 · Cited by 26
Wright, L. A.-C., & Hirsch, I. B. (2019) · Diabetic Medicine · doi:10.1111/dme.13941 · Cited by 30
Elian, V., Popovici, V., Karampelas, O., Pîrcălăbioru, G. G., Radulian, G., & Muşat, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041972 · Cited by 26
“Sotagliflozin and Dapagliflozin’s initial approval for adjunct therapy in patients with T1DM with BMI > 27 kg/m 2 poorly controlled by conventional treatment T1DM was based on the weight control benefit.”
BackgroundPasqua, M., Jafar, A., Kobayati, A., Tsoukas, M. A., & Haidar, A. (2022) · Diabetes Care · doi:10.2337/dc22-0490 · Cited by 30
Development and Future of Automated Insulin Delivery (AID) Systems
Garg, S. K., & MCVEAN, J. J. F. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0467 · Cited by 28
Self-citationSotagliflozin: A Review in Type 1 Diabetes
Deeks, E. D. (2019) · Drugs · doi:10.1007/s40265-019-01230-w · Cited by 26
Kim, Y. J., Hwang, S. D., & Lim, S. K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00553 · Cited by 24
“According to a report from the International Diabetes Federation (IDF), T1D currently affects 29 million adults worldwide (1).”
BackgroundMethodInfluentialManagement of diabetic ketoacidosis in special populations
Eledrisi, M. S., Beshyah, S., & Malik, R. A. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108744 · Cited by 27
Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Warnes, H., Helliwell, R., Pearson, S. M., & Ajjan, R. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0496-z · Cited by 27
STOUGAARD, E. B., Rossing, P. R., Vistisen, D., Banks, P. L., Girard, M., Davies, M. J., & Persson, F. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15047 · Cited by 23
“In the inTandem3 trial, after a 2-week, single-blind run-in period, during which all participants received placebo, eligible patients (similar criteria as in inTandem1 and 2) were randomly assigned, in a 1:1 ratio, to receive either once-daily sotagliflozin 400 mg or placebo as an adjunct to insulin therapy for 24 wee…”
BackgroundMethodSelf-citationPatil, T., Cook, M., Hobson, J., Kaur, A., & Lee, A. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.06.016 · Cited by 24
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally, L. M., Sherr, J. L., Name, M. A. V., Patel, A., & Tamborlane, W. V. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1597705 · Cited by 26
“8 units when compared to controls [59].”
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
Perkins, B. A., Rosenstock, J., Skyler, J. S., Laffel, L. M., Cherney, D. Z. I., Mathieu, C., Pang, C., Wood, R., Kinduryte, O., George, J. T., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0548 · Cited by 25
An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
Adeghate, E. A., Mohsin, S., Adi, F., Ahmed, F., Yahya, A., Kalász, H., Tekes, K., & Adeghate, E. A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1655539 · Cited by 23
“Unfortunately, dual SGLT2 inhibitors cause significant increases in the number of diarrhea, diabetic acidosis and hypoglycemic events [26].”
BackgroundPettus, J., Kushner, J. A., Valentine, V., Wood, R., Pang, C., Paranjape, S., Berria, R., Deluzio, A., & Edelman, S. V. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0027 · Cited by 22
Self-citationHorii, T., Oikawa, Y., Atsuda, K., & Shimada, A. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13506 · Cited by 23
SGLT-2 inhibitors in obesity and its associated cardiometabolic disorders: where do we stand?
Vallianou, N. G., Tsilingiris, D., Kounatidis, D. C., Lempesis, I. G., Karampela, Ι., & Dalamaga, Μ. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16342 · Cited by 30
A perspective on treating type 1 diabetes mellitus before insulin is needed
Tatović, D., Narendran, P., & Dayan, C. M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00816-5 · Cited by 34
dʼEmden, M. C., Amerena, J. V., Deed, G., Pollock, C. A., & Cooper, M. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.023 · Cited by 27
SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects
Janssens, B., Caerels, S., & Mathieu, C. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820938545 · Cited by 24
Lee, M. H., Paldus, B., Krishnamurthy, B., McAuley, S. A., Shah, R., Jenkins, A. J., & O’Neal, D. N. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818822986 · Cited by 22
Weight Management in Youth with Type 1 Diabetes and Obesity: Challenges and Possible Solutions
Zaharieva, D. P., Addala, A., Simmons, K. M., & Maahs, D. M. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00411-z · Cited by 21
Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes
Lytvyn, Y., Bjornstad, P., Lovshin, J. A., Boulet, G., Farooqi, M. A., LAI, V. S., TSE, J. M., Cham, L., Lovblom, L. E., Weisman, A., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.12.034 · Cited by 22
Gomez, R., Caletti, G., Arbo, B. D., Hoefel, A. L., Schneider, R., Hansen, A. W., Pulcinelli, R. R., Freese, L., Bandiera, S., Kucharski, L. C., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.131 · Cited by 21
Brommage, R., Powell, D. R., & Vogel, P. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.038224 · Cited by 23
Bepo, L., Nguyen, O. K., & Makam, A. N. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08961-x · Cited by 20
“38,39 Fourth, we lacked reliable data on additional comorbidities (i.e., heart failure, chronic kidney disease, or strokes), laboratory measures (i.e., glucose,”
New Horizons: Emerging Antidiabetic Medications
Mingrone, G., Castagneto‐Gissey, L., & Bornstein, S. R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac499 · Cited by 22
Al‐Ozairi, E., Irshad, M., Taghadom, E., SOJAN, L. G., Kandari, J. A., Alroudhan, D., & le Roux, C. W. (2023) · Obesity · doi:10.1002/oby.23677 · Cited by 21
“A similar result was also reported with the SGLT2i sotagliflozin when initiated by people with type 1 diabetes [19, 20].”
ResultA review of sotagliflozin for use in type 1 diabetes
Nuffer, W. A., Williams, B., & Trujillo, J. M. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819890527 · Cited by 20
Bode, B. W., Cengiz, E., Wadwa, R. P., Banks, P., Danne, T., Kushner, J. A., McGuire, D. K., Peters, A. L., Strumph, P., & Sawhney, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0079 · Cited by 20
Self-citationZou, H., Liu, L., Guo, J., Wang, H., Liu, S., Xing, Y., Deng, C., Xiao, Y., & Zhou, Z. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13387 · Cited by 21
Benefit–Risk Tradeoffs in Assessment of New Drugs and Devices
Kaul, S., Stockbridge, N., & Butler, J. (2020) · Circulation · doi:10.1161/circulationaha.120.048933 · Cited by 20
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes
Aktürk, H. K., Rewers, A. H., & Garg, S. K. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000423 · Cited by 21
Self-citationKowalska, K., Wilczopolski, P., Buławska, D., Młynarska, E., Rysz, J., & Franczyk, B. (2022) · Antioxidants · doi:10.3390/antiox11122500 · Cited by 23
Treating obesity in type 1 diabetes mellitus – review of efficacy and safety
Freeby, M., & Lane, K. L. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000841 · Cited by 23
Karakasis, P., Popovic, D. S., Patoulias, D., Koufakis, T., Παπάνας, Ν., Fragakis, N., & Rizzo, M. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01523-0 · Cited by 19
Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update
Kalra, S., Shetty, K., Nagarajan, V. B., & Ved, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00789-y · Cited by 22
Rodbard, H. W., Giaccari, A., Lajara, R., Stewart, J. A., Strumph, P., Oliveira, J. H., Lapuerta, P., & Castro, R. D. C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14127 · Cited by 21
“In phase 3 studies, the addition of sotagliflozin to insulin therapy significantly reduced HbA1c and body weight compared with insulin alone at week 24.(8,9,11) Given the weight gain associated with insulin intensification and the weight loss observed with SGLT inhibitors, the aim of this analysis was to evaluate whet…”
BackgroundSelf-citationPenaforte-Saboia, J. G., Montenegro, R. M., Couri, C. E. B., Batista, L. A. D. A., Montenegro, A. P. D. R., Fernandes, V. O., Akhtar, H., Negrato, C. A., Malmegrim, K. C. R., Moraes, D. A., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00331 · Cited by 19
Al-Shamasi, A.-A., Elkaffash, R., Mohamed, M., Rayan, M., Al-Khater, D., Gadeau, A., Ahmed, R., Hasan, A., Eldassouki, H., Yalcin, H. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312677 · Cited by 19
“However, the sotagliflozin group had a higher rate of DKA than the placebo group [149].”
BackgroundAdjunct therapies in treatment of type 1 diabetes
Goyal, I., Sattar, A., Johnson, M., & Dandona, P. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13078 · Cited by 18
“7% without the added risk of hypoglycemia; in fact, the rates for severe (BG < 55 mg/dL) and nocturnal hypoglycemia were even lower in the SGLT1/SGLT2 inhibitors treatment groups.(71,73) HbA1c reduction was observed despite the reduction in TDD of insulin, up to ~13%, and more significant reductions were seen in the b…”
BackgroundMethodDanne, T., Edelman, S. V., Frías, J. P., Ampudia‐Blasco, F. J., Banks, P., Jiang, W., Davies, M. J., & Sawhney, S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14271 · Cited by 20
Self-citationTeo, Y. H., Chia, A. Z. Q., Teo, Y. N., Chong, E. Y., Syn, N. L. X., Cheong, J. Y. A., Ong, H. T., Wee, C. F., Ting, A. Z. H., Tan, J. T. A., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003280 · Cited by 18
“blunting and delaying postprandial hyperglycaemia and achieving additional metabolic benefits [18,20].”
BackgroundSGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Riddle, M. C., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0041 · Cited by 18
Chen, M.-B., Xu, R.-J., Zheng, Q.-H., Zheng, X.-W., & Wang, H. (2020) · Medicine · doi:10.1097/md.0000000000020875 · Cited by 17
Sridhar, V. S., Heerspink, H. J. L., Davies, M. J., Banks, P. L., Girard, M., Garg, S. K., & Cherney, D. Z. I. (2023) · Diabetes Care · doi:10.2337/dc23-0129 · Cited by 17
“The mean age of inTandem3 participants was 43 years (1); 4.”
BackgroundInfluentialSelf-citationEfficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD
Sridhar, V. S., Odutayo, A., Garg, S. V., Danne, T., Doria, A., Mauer, M. S., Davies, M. J., Banks, P. L., Girard, M., & Cherney, D. Z. I. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000540 · Cited by 19
Self-citationNon-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
“in patients treated with sotagliflozin [74].”
MethodCersósimo, E., & Miles, J. M. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180813124645 · Cited by 18
Empagliflozin in type 1 diabetes
Mathieu, C., den Mooter, L. V., & Eeckhout, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s194688 · Cited by 19
“46%, and a change in weight of −3 kg in patients treated with 400 mg sotagliflozin versus placebo for 24 weeks (inTandem-3 study).(17) Results were confirmed in both the Tandem 1 and 2 studies,”
BackgroundShi, M., Wang, C., Ji, J. F., Cai, Q., Zhao, Q., Xi, W., & Zhang, J. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110192 · Cited by 18
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad285 · Cited by 18
Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy
Pasqua, M., Tsoukas, M. A., & Haidar, A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035411 · Cited by 18
Miyata, K. N., Zhao, S., Wu, C., Lo, C., Ghosh, A., Chénier, I., Filep, J. G., Ingelfinger, J. R., Zhang, S., & Chan, J. S. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108107 · Cited by 16
Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
Garg, S. K., & Strumph, P. (2018) · PubMed · doi:10.1056/nejmc1800394 · Cited by 15
Garg, S. K., Snell-Bergeon, J., Kaur, G., & Beatson, C. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0023 · Cited by 15
Self-citationEdwards, K., Uruska, A. A., Duda‐Sobczak, A., Zozulińska‐Ziółkiewicz, D., & Lingvay, I. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231180987 · Cited by 15
BOEDER, S. C., Davies, M. J., McGill, J. B., Pratley, R. E., Girard, M., Banks, P. L., Pettus, J., & Garg, S. K. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0605 · Cited by 16
Self-citationGeng, L., Sun, B., & Chen, Y. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15901 · Cited by 17
Skelley, J. W., Carter, B. S., & Roberts, M. Z. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s168472 · Cited by 16
“Tandem 3 also achieved statistical significance in secondary endpoints including favorable changes in HbA1c from baseline, SBP, mean daily bolus insulin dose, and body weight.(47) If approved, sotagliflozin would be the first oral therapy approved in the US to be used alongside insulin.”
BackgroundLangford, B., Evans, M., Haskins‐Coulter, T., O'Connor, M., Cant, H. E. O., Eddowes, L. A., Edmonds, C., & Tank, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13863 · Cited by 15
“could not be assessed for all studies because of inadequate information.(14,33-37) The methods of statistical analysis were largely comparable between studies, although only Lund 2008 used a full intention to treat analysis.”
MethodExpression of glucose transporters in duodenal mucosa of patients with type 1 diabetes
Bolla, A. M., Butera, E., Pellegrini, S., Caretto, A., Bonfanti, R., Zuppardo, R. A., Barera, G., Cavestro, G. M., Sordi, V., & Bosi, E. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01558-w · Cited by 15
STOUGAARD, E. B., Rossing, P. R., Cherney, D. Z. I., Vistisen, D., & Persson, F. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108257 · Cited by 15
Herring, R. A., Shojaee‐Moradie, F., Garesse, R., Stevenage, M., Jackson, N., Fielding, B. A., Mendis, A., Johnsen, S., Umpleby, A. M., Davies, M. J., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2579 · Cited by 16
Self-citationAdjunctive Treatments for Type 1 Diabetes
Nathan, D. M. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711296 · Cited by 15
Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
Vallianou, N. G., Christodoulatos, G. S., Kounatidis, D. C., & Dalamaga, Μ. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100089 · Cited by 15
“SGLT1 inhibitors act by delaying glucose absorption in the small intestine mainly, thus resulting in a decrease in the serum postprandial glucose levels [6,7].”
Liu, H., Sridhar, V. S., Perkins, B. A., Rosenstock, J., & Cherney, D. Z. I. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01471-2 · Cited by 14
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure
Bhatt, A. S., Bhatt, D. L., Steg, P. G., Szarek, M. J., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.036 · Cited by 16
Self-citation
Metadata
- Authors
- Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., Danne, T., McGuire, D. K., Kushner, J. A., Peters, A., & Strumph, P.
- Affiliations
- University of Southern California (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-14
- Volume
- 377
- Issue
- 24
- Pages
- 2337-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2755899227
- Cited by
- 417
- References
- 34
- Citations by year
- 2026: 27 · 2025: 39 · 2024: 38 · 2023: 36 · 2022: 32 · 2021: 41 · 2020: 57 · 2019: 72 · 2018: 64 · 2017: 10
- FWCI
- 43.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Wayne State University
- Alere
- University of Dundee
- Massachusetts Medical Society
- Intarcia Therapeutics
- Bigfoot Biomedical
- MannKind Corporation
- Dexcom
- AstraZeneca HealthCare Foundation
- University of Leicester
- Eisai
- Novo Nordisk
- Servier
- Mitsubishi Tanabe Pharma Corporation
- Esperion Therapeutics
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- sotagliflozin, type 1 diabetes, SGLT2 inhibitors, insulin therapy, glycemic control, HbA1c, hypoglycemia, diabetic ketoacidosis, weight loss, systolic blood pressure, insulin dose reduction, combination therapy, drug safety and efficacy, insulin pump, insulin injection
- MeSH terms
- Adolescent, Adult, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Least-Squares Analysis, Diabetic Ketoacidosis, Sodium-Glucose Transport Proteins, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.